• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

Research Brief on 3-Methoxy-1H-indazol-6-amine (CAS: 1056619-82-9): Recent Advances and Applications in Chemical Biology and Medicine

The compound 3-methoxy-1H-indazol-6-amine (CAS: 1056619-82-9) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and emerging roles in drug discovery and development. The compound's unique indazole scaffold and methoxy-amine functionalization make it a promising candidate for targeting various disease pathways, particularly in oncology and inflammation.

Recent studies have highlighted the synthetic accessibility of 3-methoxy-1H-indazol-6-amine through optimized multi-step organic reactions, including palladium-catalyzed cross-coupling and selective functional group modifications. Researchers have reported improved yields and purity profiles, which are critical for its application in high-throughput screening and structure-activity relationship (SAR) studies. The compound's physicochemical properties, such as solubility and stability under physiological conditions, have also been characterized, providing a foundation for its further development as a drug-like molecule.

In the context of biological activity, 3-methoxy-1H-indazol-6-amine has demonstrated potent inhibitory effects on key enzymes involved in inflammatory and proliferative pathways. For instance, it has been identified as a selective inhibitor of certain kinases, such as JAK and PI3K isoforms, which are implicated in autoimmune diseases and cancer. Mechanistic studies using cell-based assays and x-ray crystallography have elucidated its binding modes and interactions with active sites, offering insights for the design of more potent and selective derivatives.

Moreover, preclinical evaluations of 3-methoxy-1H-indazol-6-amine derivatives have shown promising results in animal models of cancer and chronic inflammation. Notably, some analogs exhibit favorable pharmacokinetic profiles, including oral bioavailability and minimal off-target effects, positioning them as potential candidates for clinical translation. Collaborative efforts between academic and industrial researchers are underway to optimize these compounds for human trials, with a focus on enhancing efficacy and reducing toxicity.

In conclusion, 3-methoxy-1H-indazol-6-amine represents a valuable scaffold in medicinal chemistry, with broad applicability in targeting disease-relevant pathways. Ongoing research aims to expand its therapeutic potential through structural optimization and combination therapies. This brief underscores the importance of continued investment in the exploration of this compound and its derivatives, which may lead to novel treatments for unmet medical needs.

• 2386589-88-2
• 1354225-63-0(3-Methoxy-1-methyl-1H-indazol-5-ylamine)
• 1368181-72-9(3-methoxy-1H-indazol-5-amine)
• 88279-08-7(3-ethoxy-1H-Indazole)
• 863637-29-0(2H-Indazole, 3-methoxy-)
• 1118574-49-4(3-METHOXY-5-NITRO-1H-INDAZOLE)
• 1848-41-5(3-methoxy-1H-Indazole)
• 711-94-4(3-methoxy-6-nitro-1H-indazole)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)